GilIWolfeMD

Neurology • Buffalo, NY

Neuromuscular Medicine, Neurophysiology

Professor and Chair of Neurology Irvin and Rosemary Smith Chair

Join to view full profile

Dr. Wolfe is on Doximity

As a Doximity member you'll join over two million verified healthcare professionals in a private, secure network.

Gain access to free telehealth tools, such as our “call shielding” and one-way patient texting.
Connect with colleagues in the same hospital or clinic.
Read the latest clinical news, personalized to your specialty.

See Dr. Wolfe's full profile

Already have an account?

Office
1010 Main St
Buffalo, NY 14202
Phone+1 716-323-0556

Fax+1 716-323-6674

Education & Training

University of Pennsylvania Health SystemResidency, Neurology, 1990 - 1993
University of Pennsylvania Health SystemInternship, Internal Medicine, 1989 - 1990
University of Texas Southwestern Medical SchoolClass of 1989

Certifications & Licensure

NY State Medical License 2012 - 2027
CT State Medical License 2022 - 2025
TX State Medical License 1990 - 2025
PA State Medical License 1991 - 1994
American Board of Psychiatry and Neurology Neurology
American Board of Psychiatry and Neurology Clinical Neurophysiology
American Board of Psychiatry and Neurology Neuromuscular Medicine

Awards, Honors, & Recognition

Buffalo Spree Magazine Castle Connolly, 2013-2014
CMS Meaningful Use Stage 1 Certification EpicCare Ambulatory EMR, Epic Systems Corporation, 2011-2012
Super Doctor SuperDoctors.com
Whos Who in Medicine and Healthcare Marquis Whos Who
Join now to see all

Clinical Trials

Thymectomy Trial in Non-Thymomatous Myasthenia Gravis Patients Receiving Prednisone Therapy Start of enrollment: 2006 Jun 01
Completed
Phase 3
Efficacy of Prednisone In the Treatment of Ocular Myasthenia Start of enrollment: 2011 Dec 01
Terminated
Phase 3
International Guillain-Barré Syndrome Outcome Study Start of enrollment: 2012 May 01
COMPLETED

Publications & Presentations

PubMed

1 citations
Safety and efficacy of satralizumab in patients with generalised myasthenia gravis (LUMINESCE): a randomised, double-blind, multicentre, placebo-controlled phase 3 trial.
Ali A Habib, Chongbo Zhao, Inmaculada Aban, Marcondes Cavalcante França Jr, Jorge Gustavo José
The Lancet. Neurology. 2025-02-01
Myasthenia gravis: The evolving therapeutic landscape.
Gil I Wolfe, Jonathan E Hanson, Nicholas J Silvestri
Eneurologicalsci. 2024-12-01
2 citations
Risk-Benefit Analysis of Novel Treatments for Patients with Generalized Myasthenia Gravis.
A Gordon Smith, Gil I Wolfe, Ali A Habib, Cynthia Z Qi, Hongbo Yang
Advances in Therapy. 2024-12-01

Press Mentions

COVID-19 May Complicate Neuromuscular Conditions Such as MG, Review FindsAugust 7th, 2020
Pharmacy Times Continuing Education™ to Present Specialty Pharmacy CE Symposia in Washington, D.CAugust 28th, 2019
“Chemical Plasmapheresis” Drug for Myasthenia Gravis Is Safe, Lowers Antibodies, and Produces Hints of Efficacy in Phase 2 TrialJuly 11th, 2019
Join now to see all

Other Languages

Hebrew